Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19.
Journal
The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R
Informations de publication
Date de publication:
07 12 2020
07 12 2020
Historique:
received:
02
06
2020
revised:
10
07
2020
accepted:
10
08
2020
entrez:
14
9
2020
pubmed:
15
9
2020
medline:
30
9
2020
Statut:
ppublish
Résumé
Infection with SARS-CoV-2 is causing a deadly and pandemic disease called coronavirus disease-19 (COVID-19). While SARS-CoV-2-triggered hyperinflammatory tissue-damaging and immunothrombotic responses are thought to be major causes of respiratory failure and death, how they relate to lung immunopathological changes remains unclear. Neutrophil extracellular traps (NETs) can contribute to inflammation-associated lung damage, thrombosis, and fibrosis. However, whether NETs infiltrate particular compartments in severe COVID-19 lungs remains to be clarified. Here we analyzed postmortem lung specimens from four patients who succumbed to COVID-19 and four patients who died from a COVID-19-unrelated cause. We report the presence of NETs in the lungs of each COVID-19 patient. NETs were found in the airway compartment and neutrophil-rich inflammatory areas of the interstitium, while NET-prone primed neutrophils were present in arteriolar microthrombi. Our results support the hypothesis that NETs may represent drivers of severe pulmonary complications of COVID-19 and suggest that NET-targeting approaches could be considered for the treatment of uncontrolled tissue-damaging and thrombotic responses in COVID-19.
Identifiants
pubmed: 32926097
pii: 152084
doi: 10.1084/jem.20201012
pmc: PMC7488867
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2020 Radermecker et al.
Déclaration de conflit d'intérêts
Disclosures: E. Cavalier reported "other" from Diasorin, Fujirebio, BioMerieux, IDS, Menarini, and Nittobo outside the submitted work. No other disclosures were reported.
Références
Nature. 2020 Jul;583(7818):830-833
pubmed: 32380511
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Pediatr Pulmonol. 2011 Jun;46(6):545-53
pubmed: 21438174
Am J Pathol. 2018 Jan;188(1):135-148
pubmed: 29107075
Thorax. 2019 Aug;74(8):768-779
pubmed: 31142617
Thromb Haemost. 2020 Jul;120(7):1004-1024
pubmed: 32473596
J Immunol. 2013 Feb 1;190(3):1217-26
pubmed: 23267025
Am J Pathol. 2011 Jul;179(1):199-210
pubmed: 21703402
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):843-853
pubmed: 29472233
Crit Care. 2018 Dec 27;22(1):358
pubmed: 30587204
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Blood. 2020 Sep 3;136(10):1169-1179
pubmed: 32597954
J Clin Invest. 2004 Jul;114(1):104-11
pubmed: 15232617
Nat Commun. 2019 Apr 23;10(1):1916
pubmed: 31015489
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
N Engl J Med. 1994 Sep 8;331(10):637-42
pubmed: 7503821
Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1382-9
pubmed: 24790143
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
BMC Cancer. 2018 Jun 22;18(1):678
pubmed: 29929491
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Respir Investig. 2020 Sep;58(5):419-420
pubmed: 32611518
Front Immunol. 2016 Sep 19;7:366
pubmed: 27698656
Cells. 2020 Jun 02;9(6):
pubmed: 32498376
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
J Thromb Haemost. 2014 Jun;12(6):860-70
pubmed: 24674135
J Inflamm Res. 2012;5:137-40
pubmed: 23293532
Clin Sci (Lond). 2020 Jun 26;134(12):1295-1300
pubmed: 32543703
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
Front Immunol. 2019 Jan 24;10:28
pubmed: 30733719
Thromb Res. 2020 Jul;191:26-27
pubmed: 32360977
Front Pharmacol. 2020 Jun 05;11:870
pubmed: 32581816
JCI Insight. 2020 Jun 18;5(12):
pubmed: 32427582
Front Immunol. 2016 Aug 15;7:311
pubmed: 27574522
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Nat Rev Immunol. 2018 Feb;18(2):134-147
pubmed: 28990587
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
Chest. 2019 Oct;156(4):774-782
pubmed: 31265835
Circ Res. 2015 Mar 27;116(7):1182-92
pubmed: 25547404
Thromb Haemost. 2020 Aug;120(8):1233-1236
pubmed: 32455440
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Nat Med. 2017 Mar 7;23(3):279-287
pubmed: 28267716
Trials. 2020 Jun 19;21(1):548
pubmed: 32560746
Nat Med. 2017 Jun;23(6):681-691
pubmed: 28459437
Med Hypotheses. 2020 Oct;143:109906
pubmed: 32505910
Anesthesiology. 2019 Apr;130(4):581-591
pubmed: 30676417
JCI Insight. 2018 Feb 8;3(3):
pubmed: 29415887
J Clin Invest. 2012 Jul;122(7):2661-71
pubmed: 22684106
Oncotarget. 2016 Apr 12;7(15):19327-40
pubmed: 27034012
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Arthritis Rheumatol. 2017 Mar;69(3):655-667
pubmed: 27696751
Anesthesiology. 2015 Apr;122(4):864-75
pubmed: 25665049
Nat Immunol. 2019 Nov;20(11):1444-1455
pubmed: 31591573
J Thromb Haemost. 2020 Aug;18(8):1859-1865
pubmed: 32459046
Science. 2015 Jul 17;349(6245):316-20
pubmed: 26185250
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32329756
J Pathol. 2014 Jul;233(3):294-307
pubmed: 24740698
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
Front Immunol. 2016 Aug 02;7:289
pubmed: 27531997
Cell Death Differ. 2019 Mar;26(3):395-408
pubmed: 30622307
Semin Thromb Hemost. 2019 Feb;45(1):86-93
pubmed: 30634198
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Nature. 2020 Jul;583(7816):437-440
pubmed: 32434211
Inflamm Res. 2017 Mar;66(3):227-237
pubmed: 27853847